American Society of Hematology

Figure 2.

$Figure 2. PK11195 significantly increases DOX and GO cytotoxicity in Pgp+- and MRP+- coexpressing AML cells. The cytotoxicities of DOX (1 μM and 2.5 μM) and GO (10 ng/mL and 40 ng/mL) were measured in TF1 AML cells and the treated live cell fractions displayed relative to untreated live cell fractions. Minimally toxic doses of both PK11195 (75 μM) and CSA (2.5 μg/mL) significantly increased DOX and GO cytotoxicity. *P < .05, **P < .01 compared to untreated cells; #P < .05, ##P < .01, ###P < .0001 compared to cells treated with DOX or GO alone. Data are shown as mean ± SEM from up to 5 independent experiments performed in duplicate or triplicate wells.$

PK11195 significantly increases DOX and GO cytotoxicity in Pgp⁺- and MRP⁺- coexpressing AML cells. The cytotoxicities of DOX (1 μM and 2.5 μM) and GO (10 ng/mL and 40 ng/mL) were measured in TF1 AML cells and the treated live cell fractions displayed relative to untreated live cell fractions. Minimally toxic doses of both PK11195 (75 μM) and CSA (2.5 μg/mL) significantly increased DOX and GO cytotoxicity. ^*P < .05, ^**P < .01 compared to untreated cells; ^#P < .05, ^##P < .01, ^###P < .0001 compared to cells treated with DOX or GO alone. Data are shown as mean ± SEM from up to 5 independent experiments performed in duplicate or triplicate wells.

This Feature Is Available To Subscribers Only